

## TABLE OF CONTENTS

	PAGE
<b>ETHICS COMMITTEE APPROVAL</b>	<b>ii</b>
<b>DECLARATION</b>	<b>iii</b>
<b>DEDICATION</b>	<b>iv</b>
<b>ABSTRACT</b>	<b>v</b>
<b>ACKNOWLEDGEMENTS</b>	<b>vii</b>
<b>TABLE OF CONTENTS</b>	<b>viii</b>
<b>LIST OF FIGURES</b>	<b>x</b>
<b>LIST OF TABLES</b>	<b>xi</b>
<b>CHAPTER 1</b>	
<b>1.1</b> Introduction	<b>1</b>
<b>1.2</b> Thyroid Physiology	<b>2</b>
<b>1.3</b> Hyperthyroidism	<b>3</b>
<b>1.4</b> Primary Hypothyroidism	<b>4</b>
<b>1.5</b> Secondary Hypothyroidism	<b>5</b>
<b>1.6</b> Tertiary Hypothyroidism	<b>6</b>
<b>1.7</b> Autoimmune Disease	<b>6</b>
<b>1.8</b> Graves Disease	<b>6</b>
<b>1.9</b> Thyroiditis	<b>6</b>
<b>1.10</b> Diagnostic Modalities in Thyroid Disease	<b>7</b>
<b>1.11</b> Diagnostic Testing	<b>7</b>
<b>1.12</b> Tests of Thyroid Function	<b>8</b>
<b>1.13</b> Total Thyroxine (tt4) and Triiodothyronine (tt3)	<b>8</b>
<b>1.14</b> Free Thyroxine (FT4) and Free Triiodothyronine (FT3)	<b>8</b>
<b>1.15</b> Thyroid Stimulating Hormone (TSH)	<b>9</b>
<b>1.16</b> Thyroglobulin	<b>10</b>
<b>1.17</b> Clinical Practice Guidelines	<b>10</b>
<b>1.18</b> Implementing Clinical Practice Guidelines	<b>11</b>
<b>1.19</b> Computers for Guideline Implementation	<b>12</b>
<b>1.20</b> Limitations of Clinical Practice Guidelines	<b>13</b>
<b>1.21</b> Poorly Crafted Guidelines	<b>13</b>

1.22	Guideline Maintenance	14
1.23	Stifled Flexibility and Innovation	14
1.24	Potential for Increased Resource Utilization	14
 <b>CHAPTER 2</b>		
2.1	Aim	16
2.2	Methodology	16
2.2.1	Inclusion Criteria	16
2.2.2	Exclusion Criteria	16
 <b>CHAPTER 3</b>		
3.1	Results	18
3.2	Requested Frequency of Tests	18
3.3	Statistical Representation of Results	20
3.4	Summary of Statistical Analysis for Specific Tests	22
3.5	Fisher Exact Test	22
3.6	Cost Comparison	22
 <b>CHAPTER 4</b>		
4.1	Data Analysis and Discussion	25
4.2	Requested Frequency of Tests	25
4.3	Fisher Exact Test	27
4.4	Results of Cost Comparison	27
 <b>CHAPTER 5</b>		
5.1	Conclusion	29
5.2	Limitations of the Study	30
5.3	Recommendations	30
5.4	Recommendations for further research	30
 <b>REFERENCES</b>		 42
<b>APPENDICES</b>		xii

## LIST OF FIGURES

Figure		Page
1	Hypothalamic-Pituitary-Axis	3
2	Components of Physician Adherence to Guidelines	12

## **LIST OF TABLES**

<b>Table</b>	<b>Page</b>
<b>1</b> Results of Pilot Study	<b>x</b>
<b>1.1</b> Thyroid Function Tests	<b>2</b>
<b>1.2</b> Aetiology of Primary Hypothyroidism	<b>5</b>
<b>1.3</b> Impact of Clinical Practice Guidelines	<b>13</b>
<b>3.2.1</b> Requested Frequency Before March 2003	<b>18</b>
<b>3.2.2</b> Requested Frequency After March 2003	<b>19</b>
<b>3.3.1</b> TSH	<b>20</b>
<b>3.3.2</b> FT3	<b>20</b>
<b>3.3.3</b> FT4	<b>20</b>
<b>3.3.4</b> FT4 and FT3	<b>20</b>
<b>3.3.5</b> TSH and FT3	<b>20</b>
<b>3.3.6</b> FT4 and TSH	<b>21</b>
<b>3.3.7</b> FT4 and TSH and FT3	<b>21</b>
<b>3.4</b> Summary of Statistical Analysis	<b>22</b>
<b>3.6.1</b> Change in Membership – Discovery Health (2002-2004)	<b>23</b>
<b>3.6.2</b> Normalised Cost Comparison For TSH	<b>23</b>
<b>3.6.3</b> Normalised Cost Comparison For Free T4	<b>23</b>
<b>3.6.4</b> Normalised Cost Comparison For Free T3	<b>24</b>
<b>3.6.5</b> Normalised Cost Comparison For the Combination Of Free T4 and TSH	<b>24</b>
<b>3.6.6</b> Normalised Cost Comparison For the Combination Of Free T4 and Free T3	<b>24</b>

## **APPENDICES**

<b>Appendix</b>		<b>Page</b>
<b>A</b>	Evidence-Based Benefits Thyroid Function Testing	<b>34</b>
<b>B</b>	Data Reporting Form	<b>36</b>